drugset / Trial / NCT00192270
Trial to Assess Safety, Tolerability, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A and B, Live Cold-adapted (CAIV-T) in Healthy Children
Phase 2
Completed
498 enrolled
MedImmune LLC
Wyeth is now a wholly owned subsidiary of Pfizer · collab
Non-randomizedSingle-groupOpen-labelPrevention
Summary
The study was designed to determine the number of doses of CAIV-T required to effectively immunize children and adolescents in the 6 to 17 year age group.
Timeline
- Start
- 2000-10
- Primary completion
- 2001-01
- Completion
- 2001-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FluMist | Vaccine | 0.2 ml | Intranasal |
Indications
No indication recorded.